Table 1 Demographic and baseline characteristics of patients with MO secondary to BRVO in the year 1 cohort by injection frequency during year 1.

From: Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion

Characteristic

Total (N = 3099)

Injection subcohort

≤6 injections (n = 1197)

≥7 injections (n = 1902)

Age, mean, years

72

73

71

Female, n (%)

1678 (54)

653 (55)

1025 (54)

VA, letters

 Mean

52

53

52

 Median

60

60

59

VA subgroup, n (%)

 ≥20/40

718 (23)

302 (25)

416 (22)

 <20/40–20/100

1487 (48)

557 (47)

930 (49)

 <20/100–20/200

467 (15)

175 (15)

292 (15)

 <20/200

427 (14)

163 (14)

264 (14)

Eyes receiving steroids and/or laser in year 1, n (%)

697 (22)

295 (25)

402 (21)

 Number of such treatments, mean (range)

7.0 (2–13)

4.3 (2–6)

9.5 (7–13)

  1. VA is reported in approximate Snellen equivalent converted from ETDRS letters.
  2. BRVO branch retinal vein occlusion, ETDRS Early Treatment Diabetic Retinopathy Study, MO macular oedema, VA visual acuity.
Back to article page